Showing results (641-650 of 678) with videos related to

Sort By:
Pageof 68
Journal of Hepatocellular Carcinoma|September 16, 2021
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular CarcinomaAhmed Omar Kaseb, S Cheenu Kappadath, Sunyoung S Lee, et al.
Neuroendocrinology|May 30, 2017
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown PrimarySimron Singh, Carlo Carnaghi, Roberto Buzzoni, et al.
Cancers|April 13, 2024
Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm StudyMatheus Sewastjanow-Silva, Lianchun Xiao, Graciela N Gonzalez, et al.
ESMO Open|February 22, 2025
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2S Stintzing, J Tabernero, T Satoh, et al.
Pancreas|April 18, 2013
Consensus guidelines for the management and treatment of neuroendocrine tumorsPamela L Kunz, Diane Reidy-Lagunes, Lowell B Anthony, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|November 14, 2018
[Expression of type 1 and type 2 cytokines from serum of coal miners and the evaluation in surveillance of coal workers' pneumoconiosis at earlier stage]S Q Yao, N W Yang, F F Guo, et al.
International Forum of Allergy & Rhinology|September 15, 2018
International assessment of inter- and intrarater reliability of the International Frontal Sinus Anatomy Classification systemRicardo Villarreal, Bozena B Wrobel, Luis F Macias-Valle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2009
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trialJames C Yao, Catherine Lombard-Bohas, Eric Baudin, et al.
Oncotarget|December 6, 2022
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patientsYehia I Mohamed, Dan G Duda, Muhammad O Awiwi, et al.
The Oncologist|December 30, 2023
Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging FeaturesHop S Tran Cao, Russell G Witt, Khaled M Elsayes, et al.
Pageof 68